

Press Release

February 15, 2007 8:00:00 AM

2006 Nobel Laureate Roger Kornberg to Join Epiphany Biosciences' Scientific Advisory Board

SAN FRANCISCO, Calif., February 15, 2007 -- Epiphany Biosciences Inc. announced today that preeminent biochemist and structural biologist Roger D. Kornberg, PhD is joining the Epiphany Scientific Advisory Board (SAB). Dr. Kornberg is a professor of structural biology and the Mrs. George A. Winzer Professor of Medicine at the Stanford University School of Medicine where his research is focused on understanding the fundamental workings of gene regulation. Prof. Kornberg was awarded the 2006 Nobel Prize in Chemistry for his studies of the molecular basis of eukaryotic transcription, the biological process by which genetic information from DNA is copied to RNA.

Prof. Kornberg obtained his PhD from Stanford University and did his postdoctoral studies with Aaron Klug and Francis Crick at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge (UK) where he discovered the nucleosome. His Nobel Prize-winning work included discovery of Mediator, a protein complex required to facilitate gene transcription, as well the solution of the three-dimensional crystal structure of RNA polymerase II, the most complex protein structure solved to date.

"I'm looking forward to joining a very distinguished and accomplished group of scientists as part of Epiphany's SAB. The diversity of the Epiphany therapeutic pipeline is exciting and I look forward to helping the company translate its unique vision into products that significantly impact human health," said Prof. Kornberg.

"We are delighted that Prof. Kornberg is joining the Epiphany SAB," noted Epiphany founder and CEO Fred Volinsky, MD. "He has been a pioneer in elucidating some of the most complicated and fundamental processes in biology. His insight into the basic mechanisms of disease will be instrumental to Epiphany's drug discovery and development efforts."

"With the addition of Prof. Kornberg, Epiphany has assembled a truly world-class team of scientists and clinicians, including co-founder Dr. Robert Gallo, co-discoverer of HIV and HTLV. We believe their involvement validates Epiphany's drug development philosophy and our mission to bring life improving therapies to patients with acute and chronic disease," stated COO and co-founder, Dr. David Myles.

About Epiphany Biosciences

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella zoster virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).

SOURCE Epiphany Biosciences, Inc.